12月19日，创业黑马、奥雅股份、润泽科技、亚康股份、锐捷网络、星宸科技、并行科技、广脉科技、 光环新网等十余只算力概念股掀起涨停潮。 截至收盘，浪潮信息、创业黑马、光迅科技位列19日龙虎榜净买入额前三，净买入额分别为6.36亿元、 2.53亿元、1.79亿元。 这一现象背后，反映了市场对算力产业发展前景的乐观预期。 有受访人士认为，AI头部企业的投入依然是洞察算力市场需求的关键窗口，政策的持续引导和技术的 不断进步，更是为算力产业的蓬勃发展注入了源源不断的动力。 概念股狂飙 从个股基本面来看，多家上市公司在算力板块深耕已久。 其中，润泽科技已在京津冀·廊坊、长三角·平湖、大湾区·佛山和惠州、成渝经济圈·重庆、甘肃·兰州和 海南·儋州等全国6大区域建成了7个AIDC智算基础设施集群。 南凌科技在算力方面拥有边缘云计算产品，可以为企业提供稳定、高性能、功能丰富的边缘计算和网络 服务。 佳力图方面透露，公司自成立以来一直专注于数据中心等精密环境控制领域方面的技术研发，为客户提 供稳定、绿色、节能的一体化解决方案及服务。 对于算力板块集体反弹，有业内人士指出，头部企业增加算力投入，以支持模型训练、推理等运算任 务， ...

12月19日，创业黑马、奥雅股份、润泽科技、亚康股份、锐捷网络、星宸科技、并行科技、广脉科技、 光环新网等十余只算力概念股掀起涨停潮。 截至收盘，浪潮信息、创业黑马、光迅科技位列19日龙虎榜净买入额前三，净买入额分别为6.36亿元、 2.53亿元、1.79亿元。 这一现象背后，反映了市场对算力产业发展前景的乐观预期。 有受访人士认为，AI头部企业的投入依然是洞察算力市场需求的关键窗口，政策的持续引导和技术的 不断进步，更是为算力产业的蓬勃发展注入了源源不断的动力。 概念股狂飙 从个股基本面来看，多家上市公司在算力板块深耕已久。 其中，润泽科技已在京津冀·廊坊、长三角·平湖、大湾区·佛山和惠州、成渝经济圈·重庆、甘肃·兰州和 海南·儋州等全国6大区域建成了7个AIDC智算基础设施集群。 南凌科技在算力方面拥有边缘云计算产品，可以为企业提供稳定、高性能、功能丰富的边缘计算和网络 服务。 佳力图方面透露，公司自成立以来一直专注于数据中心等精密环境控制领域方面的技术研发，为客户提 供稳定、绿色、节能的一体化解决方案及服务。 对于算力板块集体反弹，有业内人士指出，头部企业增加算力投入，以支持模型训练、推理等运算任 务， ...

KdT has formed a new company to develop NGM313 in a rare disease indicationNGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the new company SOUTH SAN FRANCISCO, Calif. and AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) and KdT Ventures today announced the signing of a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho recep ...

财联社12月17日讯，今日27股涨停，35股炸板，封板率为43%，友阿股份、益民集团5连板，日丰股份4 连板，天娱数科12天7板，粤传媒8天6板，诺邦股份7天4板，鑫科材料8天4板，上海凤凰4天3板。盘面 上，个股普跌，高位股集体退潮，全市场超4700只个股下跌，逾150只个股跌停。沪深两市全天成交额 1.51万亿，较上个交易日缩量1894亿。板块方面，足球概念、元件、白酒等少数板块上涨，影视、IP经 济、冰雪产业、零售等板块跌幅居前。截至收盘，沪指跌0.73%，深成指跌0.35%，创业板指跌0.02%。 人气及连板股分析 连板股晋级率降至15%，3板以上连板股家数降至仅剩4家。近期持续松动的高位股今日几乎全线溃败， 连板高度降至5板，连板最高标宜宾纸业止步7连板，盘中一度上演天地板，另外三维通信等多只人气股 盘中亦走出天地板。使得全天超百家非ST个股跌停，微盘股成为其中的杀跌重灾区，整个微盘股指数 跌近6%。不过上海凤凰、开开实业等部分近期低位新崛起的连板个股盘中出现尝试反核修复动作，加 上电声股份等部分20CM个股午后获得抄底资金回流一度展开快速修复，或标志着短线分歧今日出清临 近尾声。 主线热点 昨日举 ...

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, t ...

In 2022, Amazon introduced the Buy with Prime button, allowing premium subscribers to make purchases using their Amazon account even when shopping on other websites.Now the company is bringing a similar concept to its cloud-computing business.At its Reinvent conference in Las Vegas on Wednesday, Amazon Web Services said a new Buy with AWS button will be available for cloud software partners to embed on their sites as a way for customers to pay.AWS is the leading provider of cloud infrastructure, ahead of Mi ...

Billionaire hedge fund manager Ken Griffin just raised Citadel's position in global-consulting powerhouse Accenture.No other company has benefited more from the artificial intelligence (AI) revolution than Nvidia. The company's compute and networking products are connected to just about every single application in generative AI in some form or fashion.Given its influence on the generational opportunity AI presents, it's not shocking to learn that investors have been eagerly buying Nvidia stock in droves ove ...

Even as consumers have experienced some continued stress from the prior period of high inflation, Walmart (WMT -1.04%) continues to be one of the biggest winners in the retail space. The retail giant posted another strong quarter of sales and took a positive view on the upcoming holiday season.The stock is now up more than 60% year to date, as of this writing. The question for investors is, can the momentum in the stock continue? Let's take a closer look at its most recent results and guidance to help find ...

“Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation (“Channel” or the “Company”) ...

Core Insights - The Phase 2 data supports the proof-of-concept for efgartigimod SC in treating myositis, leading to the decision to continue development in the Phase 3 ALKIVIA study across all three myositis subtypes [1][2] - Efgartigimod SC has the potential to be the first targeted treatment for myositis patients with limited existing options [1][2] Study Design - The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter Phase 2/3 trial involving 240 patients, focusing on idiopathic inflammatory myopathies (IIM) across three subtypes: IMNM, ASyS, and DM [3] - The primary endpoint is the mean total improvement score (TIS) at 24 weeks for Phase 2 and 52 weeks for Phase 3, with key secondary endpoints including response rates and quality of life measures [3] Efficacy and Safety - The Phase 2 portion of the ALKIVIA study met its primary endpoint, showing a statistically significant treatment effect in mean TIS at Week 24, with improvements across all six core set measures compared to placebo [2][3] - The safety and tolerability profile of efgartigimod SC was consistent with previous clinical trials [2] Background on Myositis - Idiopathic inflammatory myopathies (myositis) are rare autoimmune diseases that can severely impact muscle function and quality of life, affecting multiple organs [4] - The classification of myositis has evolved, with new subtypes like IMNM and ASyS emerging alongside traditional classifications [4][5] About Efgartigimod SC - Efgartigimod SC is a human IgG1 antibody fragment designed to reduce pathogenic IgG antibodies by blocking the IgG recycling process, currently evaluated in over 15 severe autoimmune diseases [6] - It is the first approved FcRn blocker globally, marketed under various names for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy [6] Company Overview - Argenx is a global immunology company focused on developing novel antibody-based medicines for severe autoimmune diseases, partnering with academic researchers to translate immunology breakthroughs into effective treatments [7]